|
A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)
RECRUITINGPhase 2Sponsored by Chinese University of Hong Kong
Actively Recruiting
PhasePhase 2
SponsorChinese University of Hong Kong
Started2026-10-05
Est. completion2027-12-31
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07568236
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study to investigates the efficacy of fezolinetant in men undergoing ADT for prostate cancer in alleviating Vasomotor syndromes.
Eligibility
Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria: 1. Patients aged at least 18 years old on the index date 2. Histologically confirmed prostatic adenocarcinoma with localised or metastatic disease 3. Karnofsky index score of 70% or more 4. Started on androgen deprivation therapy (both medical or surgical), for at least 3 months at baseline 5. Baseline daily hot flush score ≥4 Exclusion Criteria: 1. Patients treated with drugs related to the study medications or with potential effect for vasomotor symptoms, including selective serotonin-re-uptake inhibitors, steroid hormones, clonidine, gabapentin, veralipride, or β-alanine 2. Concomitant use of CYP1A2 inhibitors, e.g. fluoroquinolone, fluovoxamine, cimetidine, propranolol, verapamil, acyclovir, allopurinol, theophylline, etc. 3. Active liver disease including: \- cirrhosis - liver failure - jaundice - elevated total or direct bilirubin - abnormal ALT / AST - abnormal INR 4. Severe (eGFR 15 to less than 30 mL/min/1.73 m2) renal impairment or end-stage renal disease (eGFR less than 15 mL/min/1.73 m2)
Conditions3
CancerProstate CancerVasomotor Symptoms
Interventions1
Related trials
- A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer — Astellas Pharma Global Development, Inc.
- FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy — Yale University
- Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer — University of Vermont
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorChinese University of Hong Kong
Started2026-10-05
Est. completion2027-12-31
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07568236